Cochlear Implant Fitting Methods for Hearing Loss
(CALOS4 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores new ways to fine-tune cochlear implants for individuals who lost their hearing after learning to speak. It compares two fitting methods—behavioral fitting and categorical loudness scaling-based fitting—to determine which one enhances hearing and comfort. Individuals with a cochlear implant who experienced severe hearing loss after age two may qualify. Participants will try both fitting methods over several weeks, aiding researchers in improving future cochlear implant programming. As an unphased trial, this study allows participants to contribute to advancements in cochlear implant technology and improve outcomes for future users.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that these cochlear implant fitting methods are safe?
Research shows that cochlear implants, which assist people with severe hearing loss, are generally safe. The Categorical Loudness Scaling method adjusts the implant by providing information about perceived sound loudness. Studies have not reported specific negative effects from this method.
For the Behavioural Fitting method, research indicates that cochlear implants are safe and effective. Most side effects from cochlear implant surgeries are minor and temporary. People typically adjust well to the device, enhancing their hearing and quality of life.
Overall, both methods for adjusting cochlear implants are well-tolerated and considered safe based on available research.12345Why are researchers excited about this trial?
Researchers are excited about the trial for cochlear implant fitting methods because it explores innovative ways to enhance hearing outcomes for people with hearing loss. Unlike standard fitting techniques, which might not always perfectly match individual needs, this trial examines both behavioral fitting and categorical loudness scaling-based fitting. These methods aim to tailor the cochlear implant experience more precisely to each user, potentially leading to better sound perception and overall satisfaction. By offering a personalized approach, this trial could pave the way for more effective and user-friendly hearing solutions.
What evidence suggests that these cochlear implant fitting methods are effective for hearing loss?
Research has shown that two methods, categorical loudness scaling and behavioral fitting, are promising for effectively setting up cochlear implants. In this trial, participants will receive both categorical loudness scaling-based fitting and behavioral fitting. Categorical loudness scaling reliably provides consistent loudness levels across different sessions. This method adjusts implant settings based on user comfort, potentially improving hearing. Behavioral fitting enhances speech understanding and quality of life, particularly for older adults and children with cochlear implants. Both methods aim to improve hearing and quality of life by customizing implant settings to fit individual needs.678910
Who Is on the Research Team?
Anke Plasmans
Principal Investigator
Cochlear
Are You a Good Fit for This Trial?
This trial is for adults over 18 who became deaf after age 2 and now have a CI600 or CI500 series cochlear implant. Participants must understand the language used in speech tests and agree to follow the study rules.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive both Categorical Loudness Scaling Based Fitting and Behavioural Fitting with 4 weeks experience of both MAPS
Follow-up
Participants are monitored for performance outcomes and further refinement of fitting methods
What Are the Treatments Tested in This Trial?
Interventions
- Behavioural fitting
- Categorical loudness scaling based fitting
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cochlear
Lead Sponsor
Dig Howitt
Cochlear
Chief Executive Officer since 2018
BE (Hons), MBA
Michael del Prado
Cochlear
Chief Medical Officer since 2022
MD, MSc, FRACP, FAAHMS, FAICD
QbD Clinical
Industry Sponsor
QbD Clinical
Collaborator
Avania
Industry Sponsor